MedTrace Logo

Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

NCT00719966 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 109

Last updated 2024-01-02

No results posted yet for this study

Summary

RATIONALE: Aromatase inhibitor therapy is used in treating postmenopausal women who have hormone-dependent breast cancer. It is not yet known what effect aromatase inhibitor therapy has on blood vessel function.

PURPOSE: This clinical trial is studying the effect of aromatase inhibitor therapy on blood vessel function in postmenopausal women with breast cancer.

Conditions

Interventions

DRUG

anastrozole

Patients receive aromatase inhibition therapy.

DRUG

exemestane

Patients receive aromatase inhibition therapy.

DRUG

letrozole

Patients receive aromatase inhibition therapy.

PROCEDURE

assessment of therapy complications

Endothelial function is measured

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Nicole P. Sandhu, M.D., Ph.D. · Mayo Clinic

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-18
Primary Completion
2013-06-13
Completion
2020-01-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00719966 on ClinicalTrials.gov